Oncologic Drugs Advisory Committee; Cancellation, 50980 [E9-23764]
Download as PDF
<![CDATA[
50980
Federal Register / Vol. 74, No. 190 / Friday, October 2, 2009 / Notices
November 19, 2009
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institute of Environmental
Health Sciences
Food and Drug Administration
Rodbell Auditorium, Rall Building
[Docket No. FDA–2009–N–0664]
111 T.W. Alexander Drive, Research
Triangle Park, NC
Oncologic Drugs Advisory Committee;
Cancellation
pwalker on DSK8KYBLC1PROD with NOTICES
Technical Reports (TR) Scheduled for
Review
• TR 564 1–Bromopropane (CASRN
106–94–5)
Æ Previously used as an intermediate
in the production of pesticides,
quaternary ammonium compounds,
flavors, and fragrances. Introduced
as a less toxic replacement for
methylene chloride in emissive
applications such as vapor and
immersion degreasing operations
and critical cleaning of electronics
and metals. Used as a relatively
nonflammable, nontoxic, fastdrying, and inexpensive solvent for
adhesive resins, and as a
replacement for ozone-depleting
refrigerants.
• TR 565 Milk Thistle Extract (CASRN
84604–20–6)
Æ Milk thistle extracts are used as
herbal medicines to treat a variety
of diseases (e.g., liver disease) and
as a food additive.
• TR 566 Diethylamine (CASRN 109–
89–7)
Æ Used mainly as a chemical
intermediate to produce the
corrosion inhibitor, N,Ndiethylethanolamine, and to lesser
extent to produce pesticides, insect
repellants, pharmaceuticals, and
rubber processing chemicals.
• TR 567 Ginseng (CASRN 50647–08–0)
Æ Ginseng is a perennial aromatic
herb widely used in herbal
remedies for enhancing stamina and
endurance for mental and physical
performance.
• TR 563 Pulegone (CASRN 89–82–7)
Æ Several essential oils that contain
pulegone are used for flavoring
foods, drinks, and dental products,
as fragrance agents, and in herbal
medicines.
• TR 536 Bis(2-chloroethoxy) methane
(CASRN 111–91–1)
Æ Used as a solvent and as the
starting agent in the production of
fungicides and polysulfide
polymers.
[FR Doc. E9–23781 Filed 10–1–09; 8:45 am]
BILLING CODE 4140–01–P
VerDate Nov<24>2008
16:40 Oct 01, 2009
Jkt 220001
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
SUMMARY: The meeting of the Oncologic
Drugs Advisory Committee scheduled
for October 6, 2009, is cancelled. This
meeting was announced in the Federal
Register of August 25, 2009 (74 FR
42907). The October 6, 2009, Oncologic
Drugs Advisory Committee meeting was
to discuss ApoPharma, Inc.’s new drug
application (NDA) 021–825 for
proposed trade name FERRIPROX
(deferiprone) film-coated tablets. This
meeting has been cancelled to allow
time for FDA to review and resolve
several outstanding issues. The agency
intends to continue evaluating NDA
021–825 and, as needed, may schedule
an advisory committee meeting in the
future.
FOR FURTHER INFORMATION CONTACT:
Nicole Vesely, Center for Drug
Evaluation and Research (HFD–21),
Food and Drug Administration, 5600
Fishers Lane (for express delivery, 5630
Fishers Lane, rm. 1093), Rockville, MD
20857, 301–827–6793, FAX: 301–827–
6776, e-mail: nicole.vesely@fda.hhs.gov,
or FDA Advisory Committee
Information Line, 1–800–741–8138
(301–443–0572 in the Washington, DC
area), code 3014512542. Please call the
Information Line for up-to-date
information on this meeting.
Dated: September 28, 2009.
David Horowitz,
Assistant Commissioner for Policy.
[FR Doc. E9–23764 Filed 10–1–09; 8:45 am]
BILLING CODE 4160–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
PO 00000
Frm 00035
Fmt 4703
Sfmt 4703
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel, Special
Conflict.
Date: October 15, 2009.
Time: 1 p.m. to 2 p.m.
Agenda: To review and evaluate grant
applications.
Place: Melrose Hotel, 2430 Pennsylvania
Avenue, NW., Washington, DC 20037.
Contact Person: Russell T. Dowell, PhD,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4128,
MSC 7814, Bethesda, MD 20892. (301) 435–
1850. dowellr@csr.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
Name of Committee: Center for Scientific
Review Special Emphasis Panel,
Psychopathology and Adult Disorders.
Date: October 29, 2009.
Time: 8 a.m. to 3 p.m.
Agenda: To review and evaluate grant
applications.
Place: Parc 55 Hotel, 55 Cyril Magnin
Street, Market at Fifth, San Francisco, CA
94102.
Contact Person: Biao Tian, PhD, Scientific
Review Officer, Center for Scientific Review,
National Institutes of Health, 6701 Rockledge
Drive, Room 3089B, MSC 7848, Bethesda,
MD 20892. (301) 402–4411.
tianbi@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel,
Technological Innovations for
Interdisciplinary Research.
Date: October 29, 2009.
Time: 3 p.m. to 6 p.m.
Agenda: To review and evaluate grant
applications.
Place: Parc 55 Hotel, 55 Cyril Magnin
Street, Market at Fifth, San Francisco, CA
94102.
Contact Person: Biao Tian, PhD, Scientific
Review Officer, Center for Scientific Review,
National Institutes of Health, 6701 Rockledge
Drive, Room 3089B, MSC 7848, Bethesda,
MD 20892. (301) 402–4411.
tianbi@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel, Science
Education, Communication and Childhood
Disorders.
Date: October 30, 2009.
Time: 8 a.m. to 6 p.m.
Agenda: To review and evaluate grant
applications.
Place: Parc 55 Hotel, 55 Cyril Magnin
Street, Market at Fifth, San Francisco, CA
94102.
Contact Person: Biao Tian, PhD, Scientific
Review Officer, Center for Scientific Review,
National Institutes of Health, 6701 Rockledge
E:\FR\FM\02OCN1.SGM
02OCN1
]]>Agencies
[Federal Register Volume 74, Number 190 (Friday, October 2, 2009)]
[Notices]
[Page 50980]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E9-23764]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2009-N-0664]
Oncologic Drugs Advisory Committee; Cancellation
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The meeting of the Oncologic Drugs Advisory Committee
scheduled for October 6, 2009, is cancelled. This meeting was announced
in the Federal Register of August 25, 2009 (74 FR 42907). The October
6, 2009, Oncologic Drugs Advisory Committee meeting was to discuss
ApoPharma, Inc.'s new drug application (NDA) 021-825 for proposed trade
name FERRIPROX (deferiprone) film-coated tablets. This meeting has been
cancelled to allow time for FDA to review and resolve several
outstanding issues. The agency intends to continue evaluating NDA 021-
825 and, as needed, may schedule an advisory committee meeting in the
future.
FOR FURTHER INFORMATION CONTACT: Nicole Vesely, Center for Drug
Evaluation and Research (HFD-21), Food and Drug Administration, 5600
Fishers Lane (for express delivery, 5630 Fishers Lane, rm. 1093),
Rockville, MD 20857, 301-827-6793, FAX: 301-827-6776, e-mail:
nicole.vesely@fda.hhs.gov, or FDA Advisory Committee Information Line,
1-800-741-8138 (301-443-0572 in the Washington, DC area), code
3014512542. Please call the Information Line for up-to-date information
on this meeting.
Dated: September 28, 2009.
David Horowitz,
Assistant Commissioner for Policy.
[FR Doc. E9-23764 Filed 10-1-09; 8:45 am]
BILLING CODE 4160-01-S
